Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19741228.
- Also identified by DOI 10.1056/NEJMoa0810257.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We describe the clinical and therapeutic course of a 52-year-old patient with multiple sclerosis in whom progressive multifocal leukoencephalopathy (PML) developed after 12 months of therapy with natalizumab. The patient was hospitalized 2 months after the onset of neurologic and psychiatric symptoms and was treated with plasma exchange and immunoadsorption to eliminate natalizumab. After a brief improvement, he became critically ill with an apparent episode of immune reconstitution inflammatory syndrome. Steroid-pulse therapy led to stabilization of the patient's condition and clinically significant recovery. This case illustrates that prompt diagnosis and treatment may improve the outcome in patients with severe PML associated with natalizumab therapy.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Brain
- Brain/pathology
- Humans
- Immunosorbent Techniques
- Integrin alpha4
- Integrin alpha4/immunology
- JC Virus
- Leukoencephalopathy, Progressive Multifocal
- Leukoencephalopathy, Progressive Multifocal/chemically induced
- Leukoencephalopathy, Progressive Multifocal/therapy
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Multiple Sclerosis
- Multiple Sclerosis/complications
- Multiple Sclerosis/drug therapy
- Multiple Sclerosis/pathology
- Natalizumab
- Plasma Exchange